Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ruth Román-Lladó"'
Autor:
Ruth Román-Lladó, Cristina Aguado, Núria Jordana-Ariza, Jaume Roca-Arias, Sonia Rodríguez, Erika Aldeguer, Mónica Garzón-Ibañez, Beatriz García-Peláez, Marta Vives-Usano, Ana Giménez-Capitán, Andrés Aguilar, Alejandro Martinez-Bueno, María Gonzalez Cao, Florencia García-Casabal, Santiago Viteri, Clara Mayo de las Casas, Rafael Rosell, Miguel Angel Molina-Vila
Publikováno v:
Journal of Molecular Pathology, Vol 4, Iss 1, Pp 57-68 (2023)
Genetic and drug sensitivity assays on primary cultures are not only of basic but also of translational interest and could eventually aid oncologists in the selection of treatments. However, cancer cells need to be identified and differentiated from
Externí odkaz:
https://doaj.org/article/4aa6f599da1a468abb18119b19ad755f
Autor:
Marta Vives-Usano, Beatriz García Pelaez, Ruth Román Lladó, Mónica Garzón Ibañez, Erika Aldeguer, Sonia Rodriguez, Andrés Aguilar, Francesc Pons, Santiago Viteri, Carlos Cabrera, Maria José Catalán, Irene Moya, María Gonzalez Cao, Juan José García-Mosquera, Alejandro Martinez-Bueno, Ekaterina Meshoulam, Nuria Jordana, Laura Berrocal, Rafael Rosell, Miguel Angel Molina, Clara Mayo de las Casas
Publikováno v:
Journal of Molecular Pathology, Vol 2, Iss 2, Pp 123-134 (2021)
Somatic copy number variations (CNV; i.e., amplifications and deletions) have been implicated in the origin and development of multiple cancers and some of these aberrations are designated targets for therapies. Although FISH is still considered the
Externí odkaz:
https://doaj.org/article/ca772e98c22442f8b9bdad5c2f30d92d
Autor:
Ana Giménez-Capitán, Masaoki Ito, Ruth Román-Lladó, Koji Arihiro, Yukio Takeshima, Cristina Aguado, Miguel Angel Molina-Vila, Ana Pérez-Rosado, Rafael Rosell, Daisuke Ueda, Morihito Okada, Yoshihiro Miyata, Yasuhiro Tsutani, Kei Kushitani
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 147:3709-3718
The clinicopathological or genetic features related to the prognosis of mucinous adenocarcinoma are unknown because of its rarity. The clinicopathological or targetable features were investigated for better management of patients with mucinous adenoc
Autor:
Irene Moya, Beatriz García Pelaez, Andrés Aguilar, Laura Berrocal, Santiago Viteri, Maria Gonzalez Cao, Sonia Rodríguez, Marta Vives-Usano, Maria José Catalán, Erika Aldeguer, Francesc Pons, Alejandro Martinez-Bueno, Mónica Garzón Ibañez, Clara Mayo de las Casas, Nuria Jordana, Miguel Angel Molina, Ruth Román Lladó, Juan José García-Mosquera, Rafael Rosell, Carlos Cabrera, Ekaterina Meshoulam
Publikováno v:
Journal of Molecular Pathology
Volume 2
Issue 2
Pages 13-134
Journal of Molecular Pathology, Vol 2, Iss 13, Pp 123-134 (2021)
Volume 2
Issue 2
Pages 13-134
Journal of Molecular Pathology, Vol 2, Iss 13, Pp 123-134 (2021)
Somatic copy number variations (CNV
i.e., amplifications and deletions) have been implicated in the origin and development of multiple cancers and some of these aberrations are designated targets for therapies. Although FISH is still considered
i.e., amplifications and deletions) have been implicated in the origin and development of multiple cancers and some of these aberrations are designated targets for therapies. Although FISH is still considered
Autor:
Beatriz García Pelaez, Ana Giménez-Capitán, Irene Moya, Maria Gonzalez Cao, Miguel Angel Molina-Vila, Erika Aldeguer, Ruth Román Lladó, Florencia Garcia Casabal, Nuria Jordana Ariza, Carlos Cabrera, Clara Mayo de las Casas, Maria José Catalán, Marta Vives Usano, Santiago Viteri, Mónica Garzón Ibañez, Sonia Rodríguez, Cristina Aguado, Silvia Garcia-Roman, Jordi Bertran Alamillo, Andrés Aguilar, Rafael Rosell
Publikováno v:
Cancer Research. 81:290-290
Background: Fusions involving the tyrosine kinase receptor genes ALK, ROS1, RET, NTRK or MET exon 14 skipping variant (METex14) are present in a significant percentage of advanced solid tumors and their accurate identification is critical to guide ta
Autor:
Clara Mayo de las Casas, Mónica Garzón-Ibañez, Núria Jordana-Ariza, Santiago Viteri-Ramírez, Irene Moya-Horno, Niki Karachaliou, Zaira Yeste, Raquel Campos, Sergi Villatoro, Ariadna Balada-Bel, Beatriz García-Peláez, Noemí Reguart, Cristina Teixidó, Eloisa Jantús, Silvia Calabuig, Cristina Aguado, Ana Giménez-Capitán, Ruth Román-Lladó, Ana Pérez-Rosado, Maria José Catalán, Jordi Bertrán-Alamillo, Silvia García-Román, Sonia Rodriguez, Lidia Alonso, Erika Aldeguer, Alejandro Martínez-Bueno, Maria González-Cao, Andrés Aguilar Hernandez, Juan Garcia-Mosquera, Maria de los Llanos Gil, Manuel Fernandez, Rafael Rosell, Miguel Ángel Molina-Vila
Publikováno v:
Translational Cancer Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background: In a significant percentage of advanced non-small cell lung cancer (NSCLC) patients, tumor tissue is unavailable or insufficient for genetic analyses at time to progression. We prospectively analyzed the appearance of genetic alterations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89900d376e87821da5a898aa2ba2315e
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2879
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2879
Autor:
Ariadna Balada, Maria Gonzalez Cao, Noemi Reguart, Erika Aldeguer, Cristina Teixidó, Morihito Okada, Cristina Aguado Esteban, Masaoki Ito, Ana Giménez-Capitán, Miguel Angel Molina Vila, Yoshihiro Miyata, Yasuhiro Tsutani, Ueda Daisuke, Andrés Aguilar, Rafael Rosell, Sonia Rodríguez, Santiago Viteri Ramirez, Ruth Román Lladó
Publikováno v:
Cancer Research. 80:5594-5594
Introduction: Although immune checkpoint inhibitors have become a standard of care for multiple cancer types; currently used biomarkers, such as PD-L1 expression, MSI or TMB, fail to identify all responders. In addition, little is known about markers
Autor:
Niki Karachaliou, Maria de los Llanos Gil, Miguel Angel Molina Vila, Rafael Rosell, Veronika Smutna, Alejandro Martínez Bueno, Valérie Cattan, Nuria Jordana Ariza, Ruth Román Lladó, Lidia Alonso Landeira, Santiago Viteri, Maria Gonzalez Cao, Mónica Garzón Ibañez
Publikováno v:
Cancer Research. 79:2521-2521
Background Non-small cell lung cancer (NSCLC) tumors with mutations in the EGF receptor (EGFR) relapse to therapy with EGFR tyrosine kinase inhibitors (EGFR TKIs) due to a variety of mechanisms, such as emergence resistance mutations, dysregulation o
Autor:
Nadina Erill Sagalés, Anna Colomer Valero, Xavier Puig Torrus, Carlos Cordon Cardo, Montse Verdú Artufel, Ruth Román Lladó, Abelardo Moreno Carazo, Miquel Calvo Llorca
Publikováno v:
Clinical and Translational Oncology. 7:504-511
El oncogenHER2/neu es un determinante biologico predictivo esencial en el cancer de mama por su papel como diana terapeutica del trastuzumab. No obstante, no se ha llegado aun a consensuar un metodo de referencia para su estudio. En este trabajo, hem
Autor:
Montse Verdú, Artufel, Anna Colomer, Valero, Ruth Román, Lladó, Nadina Erill, Sagalés, Miquel Calvo, Llorca, Abelardo Moreno, Carazo, Carlos Cordón, Cardó, Xavier Puig, Torrus
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 7(11)
The HER2/neu proto-oncogene is frequently over-expressed in breast cancer and serves as a biological target for trastuzumab therapy. However, there is no consensus regarding the technical aspects to be used to define HER2/neu status in clinical pract